Date:8/11/2009

2,013 3,516 4,272 ----- ----- ----- ------ Total research and development 3,126 4,966 6,127 10,079 Marketing, general and administrative 1,828 1,696 3,444 3,783 ----- ----- ----- ------ Total operating expenses 4,954 6,662 9,571 13,862 ----- ----- ----- ------ Loss from operations (4,949) (6,649) (9,561) (13,835) Interest expense (1,660) (1,513) (4,004) (3,018) Interest income 3 265 10 767 Other income (expense), net (8) (6) 2,644 (12) ----- ----- ------ ------ Loss before income taxes (6,614) (7,903) (10,911) (16,098) Income tax provision ----- ----- ------ ------ Net loss ($6,614) ($7,903) ($10,911) ($16,098) ====== ====== ======= ======= Basic and diluted loss per share ($0.83) ($1.06) ($1.37) ($2.20) ===== ===== ===== ===== Weighted-average number of shares of common stock outstanding 7,974 7,440 7,959 7,307 ===== ===== ===== ===== CONDENSED CONSOLIDATED BALANCE SHEET DATA Jun 30, Dec 31, (In thousands) 2009 2008 -------------------------------------------------------------------------- (Unaudited)
'/>"/>

SOURCE Vion Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals